Polyneuron Pharmaceuticals
Ruben is a co-founder and Chief Executive Officer of Polyneuron. His drug discovery expertise, including chemical synthesis, assay development, compound screening, profiling and in vivo pharmacology led him to co-develop the anti-MAG neuropathy drug candidate PN-1007. He is an expert in the underlying core technology Antibody-Catch™. Ruben holds an M.Sc. and Ph.D. in Pharmaceutical Sciences from the University of Basel.
This person is not in any offices
Polyneuron Pharmaceuticals
2 followers
Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-Catch™ technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs.